<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20241205171050
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;ff=20241205171050" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 05 Dec 2024 22:10:52 +0000</lastbuilddate>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39633578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 5. doi: 10.1161/CIRCULATIONAHA.124.069398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk for developing HCM (highly penetrant). Recently, important polygenic contributions have also been characterized. Low penetrance sarcomere variants (LowSVs) at intermediate frequencies and effect sizes have not been systematically investigated. We hypothesize that LowSVs may be common in HCM with substantial influence on disease risk and severity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among all sarcomere variants observed in the Sarcomeric Human Cardiomyopathy Registry (SHaRe), we identified putative LowSVs defined by (1) population frequency greater than expected for highly penetrant (monogenic) HCM (allele frequency >;5×10<sup>-5</sup> in the Genome Aggregation Database, gnomAD) and (2) moderate enrichment (>;2×) in patients with HCM compared with gnomAD. LowSVs were examined for their association with disease severity and clinical outcomes. Functional effects of selected LowSVs were assessed using induced pluripotent stem cell-derived cardiomyocytes. Association of LowSVs with HCM-adjacent traits in the general population was tested using UK Biobank cardiac magnetic resonance imaging data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6045 patients and 1159 unique variants in sarcomere genes, 12 LowSVs were identified. LowSVs were collectively common in the general population (1:350) and moderately enriched in HCM (aggregate odds ratio, 14.9 [95% CI, 12.5-17.9]). Isolated LowSVs were associated with an older age of HCM diagnosis and fewer adverse events. However, LowSVs in combination with a pathogenic sarcomere variant conferred higher morbidity (eg, composite adverse event hazard ratio, 5.4 [95% CI, 3.0-9.8] versus single pathogenic sarcomere variant, 2.0 [95% CI, 1.8-2.2]; <i>P</i>&lt;0.001). An intermediate functional impact was validated for 2 specific LowSVs-<i>MYBPC3</i> c.442G>;A (partial splice gain) and <i>TNNT2</i> c.832C>;T (intermediate effect on contractile mechanics). Cardiac magnetic resonance imaging analysis of the general population revealed 5 of 12 LowSVs were significantly associated with HCM-adjacent traits without overt HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39633578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39633578</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069398>10.1161/CIRCULATIONAHA.124.069398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39633578</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Joshua K Meisner</dc:creator>
<dc:creator>Aaron Renberg</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Yao-Chang Tsan</dc:creator>
<dc:creator>Brynn Elder</dc:creator>
<dc:creator>Abbey Bullard</dc:creator>
<dc:creator>Owen Merritt</dc:creator>
<dc:creator>Sean L Zheng</dc:creator>
<dc:creator>Neal Lakdawala</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>Erin M Miller</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Euan Ashley</dc:creator>
<dc:creator>Michelle Michels</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>John C Stendahl</dc:creator>
<dc:creator>Dominic Abrahams</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew Wheeler</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Michael Previs</dc:creator>
<dc:creator>Carolyn Ho</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39633578</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069398</dc:identifier>
</item>
<item>
<title>Sickle Trait and Alpha Thalassemia Increase NOS-Dependent Vasodilation of Human Arteries Through Disruption of Endothelial Hemoglobin-eNOS Interactions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39633569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Alpha and beta globin subunits of hemoglobin interact with eNOS to restrict NO signaling in human resistance arteries. Malaria-protective genetic variants that alter the expression of alpha globin or the structure of beta globin are associated with increased NOS-dependent vasodilation. Targeting the hemoglobin-eNOS interface could potentially improve NO signaling in diseases of endothelial dysfunction such as severe malaria or chronic cardiovascular conditions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 5. doi: 10.1161/CIRCULATIONAHA.123.066003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Severe malaria is associated with impaired nitric oxide (NO) synthase (NOS)-dependent vasodilation, and reversal of this deficit improves survival in murine models. Malaria might have selected for genetic polymorphisms that increase endothelial NO signaling and now contribute to heterogeneity in vascular function among humans. One protein potentially selected for is alpha globin, which, in mouse models, interacts with endothelial NOS (eNOS) to negatively regulate NO signaling. We sought to evaluate the impact of alpha globin gene deletions on NO signaling and unexpectedly found human arteries use not only alpha but also beta globin to regulate eNOS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The eNOS-hemoglobin complex was characterized by multiphoton imaging, gene expression analysis, and coimmunoprecipitation studies of human resistance arteries. Novel contacts between eNOS and hemoglobin were mapped using molecular modeling and simulation. Pharmacological or genetic disruption of the eNOS-hemoglobin complex was evaluated using pressure myography. The association between alpha globin gene deletion and blood pressure was assessed in a population study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Alpha and beta globin transcripts were detected in the endothelial layer of the artery wall. Imaging colocalized alpha and beta globin proteins with eNOS at myoendothelial junctions. Immunoprecipitation demonstrated that alpha globin and beta globin form a complex with eNOS and cytochrome b5 reductase. Modeling predicted negatively charged glutamic acids at positions 6 and 7 of beta globin to interact with positively charged arginines at positions 97 and 98 of eNOS. Arteries from donors with a glutamic acid-to-valine substitution at beta globin position 6 (sickle trait) exhibited increased NOS-dependent vasodilation. Alpha globin gene deletions were associated with decreased arterial alpha globin expression, increased NOS-dependent vasodilation, and lower blood pressure. Mimetic peptides that targeted the interactions between hemoglobin and eNOS recapitulated the effects of these genetic variants on human arterial vasoreactivity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Alpha and beta globin subunits of hemoglobin interact with eNOS to restrict NO signaling in human resistance arteries. Malaria-protective genetic variants that alter the expression of alpha globin or the structure of beta globin are associated with increased NOS-dependent vasodilation. Targeting the hemoglobin-eNOS interface could potentially improve NO signaling in diseases of endothelial dysfunction such as severe malaria or chronic cardiovascular conditions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39633569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39633569</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066003>10.1161/CIRCULATIONAHA.123.066003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39633569</guid>
<pubDate>Thu, 05 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Steven D Brooks</dc:creator>
<dc:creator>A Parker Ruhl</dc:creator>
<dc:creator>Xianke Zeng</dc:creator>
<dc:creator>Phillip Cruz</dc:creator>
<dc:creator>Sergio A Hassan</dc:creator>
<dc:creator>Olena Kamenyeva</dc:creator>
<dc:creator>Md Abdul Hakim</dc:creator>
<dc:creator>Lauryn A Ridley</dc:creator>
<dc:creator>Bianca M Nagata</dc:creator>
<dc:creator>Juraj Kabat</dc:creator>
<dc:creator>Sundar Ganesan</dc:creator>
<dc:creator>Rachel L Smith</dc:creator>
<dc:creator>Mary Jackson</dc:creator>
<dc:creator>Jessica Nino de Rivera</dc:creator>
<dc:creator>Alison J McLure</dc:creator>
<dc:creator>Jarrett M Jackson</dc:creator>
<dc:creator>Robert O Emeh</dc:creator>
<dc:creator>Naomi Tesfuzigta</dc:creator>
<dc:creator>Kyeisha Laurence</dc:creator>
<dc:creator>Stacy Joyce</dc:creator>
<dc:creator>Christina Yek</dc:creator>
<dc:creator>Sophana Chea</dc:creator>
<dc:creator>Derron A Alves</dc:creator>
<dc:creator>Brant E Isakson</dc:creator>
<dc:creator>Jessica Manning</dc:creator>
<dc:creator>Jeremy L Davis</dc:creator>
<dc:creator>Hans C Ackerman</dc:creator>
<dc:date>2024-12-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sickle Trait and Alpha Thalassemia Increase NOS-Dependent Vasodilation of Human Arteries Through Disruption of Endothelial Hemoglobin-eNOS Interactions</dc:title>
<dc:identifier>pmid:39633569</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066003</dc:identifier>
</item>
<item>
<title>REPLY: Exercise-Based Cardiac Rehabilitation and Coronary Sinus Reducer in the Management of Stable Angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e341-e342. doi: 10.1016/j.jacc.2024.09.1228.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39632009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1228>10.1016/j.jacc.2024.09.1228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632009</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Rocco A Montone</dc:creator>
<dc:creator>Riccardo Rinaldi</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Pasquale Perrone Filardi</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Exercise-Based Cardiac Rehabilitation and Coronary Sinus Reducer in the Management of Stable Angina</dc:title>
<dc:identifier>pmid:39632009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1228</dc:identifier>
</item>
<item>
<title>Optimizing Management of Stable Angina: Lifestyle Intervention as the Third Pillar</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e339-e340. doi: 10.1016/j.jacc.2024.08.082.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39632008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.082>10.1016/j.jacc.2024.08.082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632008</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Iris A de Koning</dc:creator>
<dc:creator>Tom Vromen</dc:creator>
<dc:creator>Joyce M Heutinck</dc:creator>
<dc:creator>Hareld M C Kemps</dc:creator>
<dc:creator>Dick H J Thijssen</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Management of Stable Angina: Lifestyle Intervention as the Third Pillar</dc:title>
<dc:identifier>pmid:39632008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.082</dc:identifier>
</item>
<item>
<title>The Reducer Is a Novel, Safe, and Effective Therapy to Optimize the Management of Patients With Stable Angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):e337. doi: 10.1016/j.jacc.2024.08.083.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39632007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.083>10.1016/j.jacc.2024.08.083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632007</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shmuel Banai</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Stefan Verheye</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Reducer Is a Novel, Safe, and Effective Therapy to Optimize the Management of Patients With Stable Angina</dc:title>
<dc:identifier>pmid:39632007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.083</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):2416. doi: 10.1016/j.jacc.2024.10.107.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39632006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.107>10.1016/j.jacc.2024.10.107</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632006</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39632006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.107</dc:identifier>
</item>
<item>
<title>Major Bleeding and Mortality After Revascularization of Left Main Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39632005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In the EXCEL trial, CABG resulted in higher 5-year rates of all MB and in-hospital MB, although postdischarge MB was more frequent after PCI. MB after both procedures was associated with increased cardiovascular and noncardiovascular mortality within 5 years. (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 10;84(24):2335-2346. doi: 10.1016/j.jacc.2024.07.065.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The incidence and prognostic impact of major bleeding (MB) after percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD) are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to investigate the rates and outcomes of MB after LMCAD revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial, 1,905 patients with unprotected LMCAD were randomized to undergo PCI (n = 948) or CABG (n = 957) and followed up for 5 years. MB was defined as TIMI major or minor bleeding, BARC (Bleeding Academic Research Consortium) types 3 to 5 bleeding, or any overt bleeding requiring blood transfusion. The association between MB and subsequent mortality was assessed in time-adjusted Cox regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 5 years, 217 patients (11.4%) had at least 1 MB event. Rates of 5-year MB were 7.9% after PCI vs 14.8% after CABG (OR: 0.48; 95% CI: 0.36-0.65; P &lt; 0.0001). However, in-hospital MB was lower after PCI (3.8% vs 13.5%; OR: 0.25; 95% CI: 0.17-0.37), whereas postdischarge MB was lower after CABG (4.5% vs 2.0%; OR: 2.33; 95% CI: 1.33-3.09; P<sub>interaction</sub> &lt; 0.0001). All 41 postdischarge MB events after PCI occurred in patients receiving dual antiplatelet therapy. MB events within 5 years were associated with a higher subsequent risk of all-cause mortality (adjusted HR: 2.71; 95% CI: 1.95-3.77; P &lt; 0.0001), whether in-hospital or postdischarge (P<sub>interaction</sub> = 1.00) and after both PCI and CABG (P<sub>interaction</sub> = 0.95), driven both by increased cardiovascular and non-cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In the EXCEL trial, CABG resulted in higher 5-year rates of all MB and in-hospital MB, although postdischarge MB was more frequent after PCI. MB after both procedures was associated with increased cardiovascular and noncardiovascular mortality within 5 years. (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39632005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39632005</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.065>10.1016/j.jacc.2024.07.065</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39632005</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gennaro Giustino</dc:creator>
<dc:creator>Joseph F Sabik</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>John D Puskas</dc:creator>
<dc:creator>Dimitri Karmpaliotis</dc:creator>
<dc:creator>David E Kandzari</dc:creator>
<dc:creator>Marie-Claude Morice</dc:creator>
<dc:creator>Michael Ragosta</dc:creator>
<dc:creator>Zixuan Zhang</dc:creator>
<dc:creator>Ovidiu Dressler</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Samin K Sharma</dc:creator>
<dc:creator>Arie Pieter Kappetein</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Major Bleeding and Mortality After Revascularization of Left Main Disease</dc:title>
<dc:identifier>pmid:39632005</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.065</dc:identifier>
</item>
<item>
<title>Structure-guided design of a peripherally restricted chemogenetic system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39631393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetic tools for remotely controlling cellular signaling, neural activity, behavior, and physiology. Using a structure-guided approach, we provide a peripherally restricted Gi-DREADD, hydroxycarboxylic acid receptor DREADD (HCAD), whose native receptor is minimally expressed in the brain, and a chemical actuator that does not cross the blood-brain barrier (BBB). This was accomplished by combined mutagenesis, analoging...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 25:S0092-8674(24)01275-3. doi: 10.1016/j.cell.2024.11.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetic tools for remotely controlling cellular signaling, neural activity, behavior, and physiology. Using a structure-guided approach, we provide a peripherally restricted Gi-DREADD, hydroxycarboxylic acid receptor DREADD (HCAD), whose native receptor is minimally expressed in the brain, and a chemical actuator that does not cross the blood-brain barrier (BBB). This was accomplished by combined mutagenesis, analoging via an ultra-large make-on-demand library, structural determination of the designed DREADD receptor via cryoelectron microscopy (cryo-EM), and validation of HCAD function. Expression and activation of HCAD in dorsal root ganglion (DRG) neurons inhibit action potential (AP) firing and reduce both acute and tissue-injury-induced inflammatory pain. The HCAD chemogenetic system expands the possibilities for studying numerous peripheral systems with little adverse effects on the central nervous system (CNS). The structure-guided approach used to generate HCAD also has the potential to accelerate the development of emerging chemogenetic tools for basic and translational sciences.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39631393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39631393</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.001>10.1016/j.cell.2024.11.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39631393</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Hye Jin Kang</dc:creator>
<dc:creator>Brian E Krumm</dc:creator>
<dc:creator>Adrien Tassou</dc:creator>
<dc:creator>Matan Geron</dc:creator>
<dc:creator>Jeffrey F DiBerto</dc:creator>
<dc:creator>Nicholas J Kapolka</dc:creator>
<dc:creator>Ryan H Gumpper</dc:creator>
<dc:creator>Kensuke Sakamoto</dc:creator>
<dc:creator>D Dewran Kocak</dc:creator>
<dc:creator>Reid H J Olsen</dc:creator>
<dc:creator>Xi-Ping Huang</dc:creator>
<dc:creator>Shicheng Zhang</dc:creator>
<dc:creator>Karen L Huang</dc:creator>
<dc:creator>Saheem A Zaidi</dc:creator>
<dc:creator>MyV T Nguyen</dc:creator>
<dc:creator>Min Jeong Jo</dc:creator>
<dc:creator>Vsevolod Katritch</dc:creator>
<dc:creator>Jonathan F Fay</dc:creator>
<dc:creator>Grégory Scherrer</dc:creator>
<dc:creator>Bryan L Roth</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure-guided design of a peripherally restricted chemogenetic system</dc:title>
<dc:identifier>pmid:39631393</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.001</dc:identifier>
</item>
<item>
<title>Transthyretin Tetramer Destabilization and Increased Mortality in the General Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39630472/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 4. doi: 10.1001/jamacardio.2024.4102. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Transthyretin tetramer destabilization is the rate-limiting step in the development of transthyretin cardiac amyloidosis, an underrecognized contributor to mortality in older adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To test the hypothesis that transthyretin tetramer destabilization is associated with all-cause and cardiovascular mortality in the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this cohort study including individuals aged 20 to 80 years, genetic data were analyzed from 2 similar prospective studies of the Danish general population, the Copenhagen City Heart Study (CCHS) and the Copenhagen General Population Study (CGPS). Observational data from a subsample of the same studies where transthyretin was measured consecutively were also analyzed. In both studies, individuals were followed up from the examination date (1991-1994 in CCHS and 2003-2015 in CGPS) until death or the end of follow-up in December 2018. Data were analyzed from November 1, 2023, to August 15, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Missense variants in TTR associated with increasing transthyretin tetramer destabilization in primary genetic analyses, and plasma transthyretin level in secondary observational analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: All-cause and cardiovascular mortality identified from the national Danish Civil Registration System and the national Danish Register of Causes of Death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 102 204 individuals (median [IQR] age, 57 [47-66] years; 56 445 [55%] female) were included. Median follow-up was 10 years (range, &lt;1-27 years). In genetic analyses, p.T139M, a transthyretin tetramer stabilizing variant that is more stable than noncarriers' tetramer stability, was used as the reference. For noncarriers who have intermediate tetramer stability and for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, and p.D119N) who have the lowest tetramer stability, respective hazard ratios (HRs) were 1.37 (95% CI, 1.06-1.77) and 1.65 (95% CI, 0.95-2.88) for all-cause mortality (P for trend = .01), and 1.63 (95% CI, 0.92-2.89) and 2.23 (95% CI, 0.78-6.34) for cardiovascular mortality (P for trend = .06). Furthermore, compared with p.T139M, plasma transthyretin decreased stepwise by TTR genotype: -18% for noncarriers and -29% for heterozygotes for amyloidogenic variants (p.V142I, p.H110N, p.D119N; P for trend &lt; .001). Therefore, genetically determined, increasingly lower plasma transthyretin could be considered a surrogate marker for transthyretin tetramer destabilization. Observationally, among 19 619 individuals, noncarriers with plasma transthyretin concentrations less than 20 mg/dL vs 20 to 40 mg/dL had HRs of 1.12 (95% CI, 1.02-1.23) for all-cause mortality and 1.16 (95% CI, 0.97-1.39) for cardiovascular mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Transthyretin tetramer destabilization was associated with all-cause and cardiovascular mortality in the Danish general population. These findings may suggest a need for large-scale assays to measure transthyretin destabilization for detection of transthyretin amyloidosis before clinical manifestations emerge, since early treatment improves the prognosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39630472/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39630472</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4102>10.1001/jamacardio.2024.4102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39630472</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Mette Christoffersen</dc:creator>
<dc:creator>Anders Møller Greve</dc:creator>
<dc:creator>Louise Stig Hornstrup</dc:creator>
<dc:creator>Ruth Frikke-Schmidt</dc:creator>
<dc:creator>Børge Grønne Nordestgaard</dc:creator>
<dc:creator>Anne Tybjærg-Hansen</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transthyretin Tetramer Destabilization and Increased Mortality in the General Population</dc:title>
<dc:identifier>pmid:39630472</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4102</dc:identifier>
</item>
<item>
<title>Aspirin for Secondary Prevention of Atherosclerosis-Evidence or Dogma?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39630470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 4. doi: 10.1001/jamacardio.2024.4335. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39630470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39630470</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4335>10.1001/jamacardio.2024.4335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39630470</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aspirin for Secondary Prevention of Atherosclerosis-Evidence or Dogma?</dc:title>
<dc:identifier>pmid:39630470</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4335</dc:identifier>
</item>
<item>
<title>Error in Figure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39630461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 4. doi: 10.1001/jamacardio.2024.4925. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39630461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39630461</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4925>10.1001/jamacardio.2024.4925</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39630461</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:date>2024-12-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure</dc:title>
<dc:identifier>pmid:39630461</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4925</dc:identifier>
</item>
<item>
<title>Unfolding the Link Between Transthyretin Stability and Survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39630419/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Dec 4. doi: 10.1001/jamacardio.2024.4112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39630419/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39630419</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4112>10.1001/jamacardio.2024.4112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39630419</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Anthony Angueira</dc:creator>
<dc:creator>Sarah A Abramowitz</dc:creator>
<dc:creator>Michael G Levin</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Unfolding the Link Between Transthyretin Stability and Survival</dc:title>
<dc:identifier>pmid:39630419</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4112</dc:identifier>
</item>
<item>
<title>BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: TCF21 expression is not required to maintain the cell state of CFs in the adult heart. However, preventing the normal downregulation of TCF21 expression with injury reduces myofibroblast formation, cardiac fibrosis, and the acute cardiac hypertrophic response following 1 week of Ang II/phenylephrine stimulation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325527. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the embryonic heart. In the adult heart, TCF21 is expressed in tissue-resident fibroblasts and is downregulated in response to injury or stimuli leading to myofibroblast differentiation. These findings led to the hypothesis that TCF21 regulates fibroblast differentiation in the adult mammalian heart to affect fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Tamoxifen-inducible Cre genetic mouse models were used to permit either <i>Tcf21</i> gene deletion or its enforced expression in adult CFs. Histological and echocardiographic analyses were used, as well as transcriptomic analysis to determine the consequences of TCF21 gain-of-function and loss-of-function in vivo. Genomic <i>Tcf21</i> occupancy was identified by chromatin immunoprecipitation and sequencing in CFs. Myocardial infarction and Ang II (angiotensin II)/phenylephrine served as models of cardiac fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Acute and long-term deletion of <i>Tcf21</i> in CFs of the adult mouse heart does not alter fibroblast numbers, myofibroblast differentiation, or fibrosis. Fibroblast-specific <i>Tcf21</i> gene-deleted mice demonstrate no significant alterations in cardiac function or scar formation in response to cardiac injury compared with control mice. In contrast, enforced expression of TCF21 in CFs inhibits myofibroblast differentiation and significantly reduces cardiac fibrosis and hypertrophy in response to 1 week of Ang II/phenylephrine infusion. Mechanistically, sustained TCF21 expression prevents the induction of genes associated with fibrosis and ECM (extracellular matrix) organization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: TCF21 expression is not required to maintain the cell state of CFs in the adult heart. However, preventing the normal downregulation of TCF21 expression with injury reduces myofibroblast formation, cardiac fibrosis, and the acute cardiac hypertrophic response following 1 week of Ang II/phenylephrine stimulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39629593</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325527>10.1161/CIRCRESAHA.124.325527</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629593</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Anne Katrine Z Johansen</dc:creator>
<dc:creator>Rajesh K Kasam</dc:creator>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:creator>Suh-Chin J Lin</dc:creator>
<dc:creator>Jose G Gomez-Arroyo</dc:creator>
<dc:creator>Adenike Shittu</dc:creator>
<dc:creator>Stephanie L K Bowers</dc:creator>
<dc:creator>Yasuhide Kuwabara</dc:creator>
<dc:creator>Kelly M Grimes</dc:creator>
<dc:creator>Kathrynne Warrick</dc:creator>
<dc:creator>Michelle A Sargent</dc:creator>
<dc:creator>Tanya A Baldwin</dc:creator>
<dc:creator>Susan E Quaggin</dc:creator>
<dc:creator>Artem Barski</dc:creator>
<dc:creator>Jeffery D Molkentin</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis</dc:title>
<dc:identifier>pmid:39629593</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325527</dc:identifier>
</item>
<item>
<title>A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study demonstrates the FAP vaccine can be a therapeutic tool for cardiac fibrosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Myofibroblasts are primary cells involved in chronic response-induced cardiac fibrosis. Fibroblast activation protein (FAP) is a relatively specific marker of activated myofibroblasts and a potential target molecule. This study aimed to clarify whether a vaccine targeting FAP could eliminate myofibroblasts in chronic cardiac stress model mice and reduce cardiac fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We coadministered a FAP peptide vaccine with a CpG K3 oligonucleotide adjuvant to male C57/BL6J mice and confirmed an elevation in the anti-FAP antibody titer. After continuous angiotensin II and phenylephrine administration for 28 days, we evaluated the degree of cardiac fibrosis and the number of myofibroblasts in cardiac tissues.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that cardiac fibrosis was significantly decreased in the FAP-vaccinated mice compared with the angiotensin II and phenylephrine control mice (3.45±1.11% versus 8.62±4.79%; <i>P</i>=4.59×10<sup>-3</sup>) and that the accumulation of FAP-positive cells was also significantly decreased, as indicated by FAP immunohistochemical staining (4077±1746 versus 7327±1741 cells/mm<sup>2</sup>; FAP vaccine versus angiotensin II and phenylephrine control; <i>P</i>=6.67×10<sup>-</sup><sup>3</sup>). No systemic or organ-specific inflammation due to antibody-dependent cell cytotoxicity induced by the FAP vaccine was observed. Although the transient activation of myofibroblasts has an important role in maintaining the structural robustness in the process of tissue repair, the FAP vaccine showed no adverse effects in myocardial infarction and skin injury models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study demonstrates the FAP vaccine can be a therapeutic tool for cardiac fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39629565</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325017>10.1161/CIRCRESAHA.124.325017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629565</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shota Yoshida</dc:creator>
<dc:creator>Hiroki Hayashi</dc:creator>
<dc:creator>Takuro Kawahara</dc:creator>
<dc:creator>Shunsuke Katsuki</dc:creator>
<dc:creator>Mitsukuni Kimura</dc:creator>
<dc:creator>Rissei Hino</dc:creator>
<dc:creator>Jiao Sun</dc:creator>
<dc:creator>Ryo Nakamaru</dc:creator>
<dc:creator>Akiko Tenma</dc:creator>
<dc:creator>Masayoshi Toyoura</dc:creator>
<dc:creator>Satoshi Baba</dc:creator>
<dc:creator>Munehisa Shimamura</dc:creator>
<dc:creator>Tomohiro Katsuya</dc:creator>
<dc:creator>Ryuichi Morishita</dc:creator>
<dc:creator>Hiromi Rakugi</dc:creator>
<dc:creator>Tetsuya Matoba</dc:creator>
<dc:creator>Hironori Nakagami</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts</dc:title>
<dc:identifier>pmid:39629565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325017</dc:identifier>
</item>
<item>
<title>Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We demonstrate that PO-HF is triggered by hemodynamic stress and then sets off an autoimmune-like response against cardiac self-antigens. The antigens can be used to reduce the severity of future-onset disease, via oral tolerization, effectively acting as a protective vaccine.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.324999. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is strongly associated with inflammation. In pressure overload (PO)-induced HF, cardiac stress triggers adaptive immunity, ablation, or inhibition, which blocks disease progression. We hypothesized that PO-HF might fulfill the often-used criteria of autoimmunity: if so, the associated adaptive immune response would be not only necessary but also sufficient to induce HF; it should also be possible to identify self-antigens driving the autoimmune response. Finally, we hypothesized that such an antigen-specific response can be manipulated to preventively reduce the severity of PO-HF in a tolerizing vaccine.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used the transfer of lymphocytes or serum from PO-HF mice into healthy recipients to assess whether the adaptive response is sufficient to induce disease. We devised a novel pipeline to identify self-antigens driving the response. We immunized healthy mice with novel antigens to assess whether they induce disease. To determine whether these antigens could be present in human patients, we sought to detect existing responses against these antigens in patients with HF. Finally, we used the antigens in an oral tolerance protocol to preventively protect mice from subsequently induced PO-HF, analyzing the results with next-generation sequencing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that PO-HF fulfills the criteria of an autoimmune disease, albeit partially, and identified novel cardiac self-antigens, capable of inducing cardiac dysfunction. The novel antigens in a tolerizing vaccine formulation preemptively reduced the severity of disease triggered by subsequent application of PO, via induction of effector regulatory T cells, enabling a potent reduction of PO-driven loss of systolic function, cardiac inflammation, and proinflammatory CD4<sup>+</sup> T-cell clonal expansion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We demonstrate that PO-HF is triggered by hemodynamic stress and then sets off an autoimmune-like response against cardiac self-antigens. The antigens can be used to reduce the severity of future-onset disease, via oral tolerization, effectively acting as a protective vaccine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39629560</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324999>10.1161/CIRCRESAHA.124.324999</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629560</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Elisa Martini</dc:creator>
<dc:creator>Marco Cremonesi</dc:creator>
<dc:creator>Arianna Felicetta</dc:creator>
<dc:creator>Simone Serio</dc:creator>
<dc:creator>Simone Puccio</dc:creator>
<dc:creator>Erica Pelamatti</dc:creator>
<dc:creator>Jasper J P van Beek</dc:creator>
<dc:creator>Vasiliki Papadopoulou</dc:creator>
<dc:creator>Chiara Catalano</dc:creator>
<dc:creator>Francesca Fanuele</dc:creator>
<dc:creator>Desirée Giuliano</dc:creator>
<dc:creator>Gianluca Basso</dc:creator>
<dc:creator>Cecilia Assunta Bonfiglio</dc:creator>
<dc:creator>Cristina Panico</dc:creator>
<dc:creator>Marco Vacchiano</dc:creator>
<dc:creator>Pierluigi Carullo</dc:creator>
<dc:creator>Laura Papa</dc:creator>
<dc:creator>Carla D'Andrea</dc:creator>
<dc:creator>Naz Tuzger</dc:creator>
<dc:creator>Sergio Marchini</dc:creator>
<dc:creator>Paola Magistroni</dc:creator>
<dc:creator>Silvia Deaglio</dc:creator>
<dc:creator>Antonio Amoroso</dc:creator>
<dc:creator>Enrico Lugli</dc:creator>
<dc:creator>Gianluigi Condorelli</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Autoimmune-Like Mechanism in Heart Failure Enables Preventive Vaccine Therapy</dc:title>
<dc:identifier>pmid:39629560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324999</dc:identifier>
</item>
<item>
<title>GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39629559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Deletion of GSK3β in adipocytes activates the AMPK/HIF-2α/VEGF/VEGFR2 axis, promoting vasculature expansion within obese AT. This results in a significantly improved local microenvironment, reducing inflammation and effectively ameliorating metabolic disorders associated with obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Dec 4. doi: 10.1161/CIRCRESAHA.124.325187. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Maintaining a well-developed vascular system alongside adipose tissue (AT) expansion significantly reduces the risk of metabolic complications. Although GSK3β (glycogen synthase kinase-3 beta) is known for its role in various cellular processes, its specific functions in AT and regulation of body homeostasis have not been reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: GSK3β-floxed and GSK3α-floxed mice were crossed with adiponectin-Cre mice to generate GSK3β or GSK3α adipocyte-specific knockout mice (GSK3β<sup>ADKO</sup> and GSK3α<sup>ADKO</sup>). A comprehensive whole-body metabolism analysis was performed on obese GSK3β<sup>ADKO</sup> mice induced by a high-fat diet. RNA sequencing was conducted on AT of both obese GSK3β<sup>ADKO</sup> and GSK3α<sup>ADKO</sup> mice. Various analyses, including vessel perfusion studies, lipolysis analysis, multiplex protein assays, in vitro protein phosphorylation assays, and whole-mount histology staining, were performed on AT of obese GSK3β<sup>ADKO</sup> mice. Tube-formation experiments were performed using 3B-11 endothelial cells cultured in the conditional medium of matured adipocytes under hypoxic conditions. Chromatin precipitation and immunofluorescence studies were conducted using cultured adipocytes with GSK3 inhibition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our findings provide the first evidence that adipocyte-specific knockout of GSK3β expands AT vascularization and mitigates obesity-related metabolic disorders. GSK3β deficiency, but not GSK3α, in adipocytes activates AMPK (AMP-activated protein kinase), leading to increased phosphorylation and nuclear accumulation of HIF-2α, resulting in enhanced transcriptional regulation. Consequently, adipocytes increased VEGF (vascular endothelial growth factor) expression, which engages VEGFR2 on endothelial cells, promoting angiogenesis, expanding the vasculature, and improving vessel perfusion within obese AT. GSK3β deficiency promotes AT remodeling, shifting unhealthy adipocyte function toward a healthier state by increasing insulin-sensitizing hormone adiponectin and preserving healthy adipocyte function. These effects lead to reduced fibrosis, reactive oxygen species, and ER stress in obese AT and improve metabolic disorders associated with obesity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Deletion of GSK3β in adipocytes activates the AMPK/HIF-2α/VEGF/VEGFR2 axis, promoting vasculature expansion within obese AT. This results in a significantly improved local microenvironment, reducing inflammation and effectively ameliorating metabolic disorders associated with obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39629559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39629559</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325187>10.1161/CIRCRESAHA.124.325187</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39629559</guid>
<pubDate>Wed, 04 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Jiajia Li</dc:creator>
<dc:creator>Ping Tang</dc:creator>
<dc:creator>Dongliang Zhu</dc:creator>
<dc:creator>Lixin Tai</dc:creator>
<dc:creator>Yuan Wang</dc:creator>
<dc:creator>Tsukiko Miyata</dc:creator>
<dc:creator>James R Woodgett</dc:creator>
<dc:creator>Lijun Di</dc:creator>
<dc:date>2024-12-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>GSK3β Deficiency Expands Obese Adipose Vasculature to Mitigate Metabolic Disorders</dc:title>
<dc:identifier>pmid:39629559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325187</dc:identifier>
</item>
<item>
<title>Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>The mammalian pancreas consists of three epithelial compartments: the acini and ducts of the exocrine pancreas and the endocrine islets of Langerhans. Murine studies indicate that these three compartments derive from a transient, common pancreatic progenitor. Here, we report derivation of 18 human fetal pancreas organoid (hfPO) lines from gestational weeks 8-17 (8-17 GWs) fetal pancreas samples. Four of these lines, derived from 15 to 16 GWs samples, generate acinar-, ductal-, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 2:S0092-8674(24)01254-6. doi: 10.1016/j.cell.2024.10.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The mammalian pancreas consists of three epithelial compartments: the acini and ducts of the exocrine pancreas and the endocrine islets of Langerhans. Murine studies indicate that these three compartments derive from a transient, common pancreatic progenitor. Here, we report derivation of 18 human fetal pancreas organoid (hfPO) lines from gestational weeks 8-17 (8-17 GWs) fetal pancreas samples. Four of these lines, derived from 15 to 16 GWs samples, generate acinar-, ductal-, and endocrine-lineage cells while expanding exponentially for >;2 years under optimized culture conditions. Single-cell RNA sequencing identifies rare LGR5<sup>+</sup> cells in fetal pancreas and in hfPOs as the root of the developmental hierarchy. These LGR5<sup>+</sup> cells share multiple markers with adult gastrointestinal tract stem cells. Organoids derived from single LGR5<sup>+</sup> organoid-derived cells recapitulate this tripotency in vitro. We describe a human fetal tripotent stem/progenitor cell capable of long-term expansion in vitro and of generating all three pancreatic cell lineages.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39626658</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.044>10.1016/j.cell.2024.10.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626658</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Amanda Andersson-Rolf</dc:creator>
<dc:creator>Kelvin Groot</dc:creator>
<dc:creator>Jeroen Korving</dc:creator>
<dc:creator>Harry Begthel</dc:creator>
<dc:creator>Maaike A J Hanegraaf</dc:creator>
<dc:creator>Michael VanInsberghe</dc:creator>
<dc:creator>Fredrik Salmén</dc:creator>
<dc:creator>Stieneke van den Brink</dc:creator>
<dc:creator>Carmen Lopez-Iglesias</dc:creator>
<dc:creator>Peter J Peters</dc:creator>
<dc:creator>Daniel Krueger</dc:creator>
<dc:creator>Joep Beumer</dc:creator>
<dc:creator>Maarten H Geurts</dc:creator>
<dc:creator>Anna Alemany</dc:creator>
<dc:creator>Helmuth Gehart</dc:creator>
<dc:creator>Françoise Carlotti</dc:creator>
<dc:creator>Eelco J P de Koning</dc:creator>
<dc:creator>Susana M Chuva de Sousa Lopes</dc:creator>
<dc:creator>Alexander van Oudenaarden</dc:creator>
<dc:creator>Johan H van Es</dc:creator>
<dc:creator>Hans Clevers</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages</dc:title>
<dc:identifier>pmid:39626658</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.044</dc:identifier>
</item>
<item>
<title>Artificial intelligence-derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626169/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The AI-derived ECG aging was associated with the risk of new- and early-onset AF, suggesting its potential utility to identify individuals for AF prevention across diverse populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae790. doi: 10.1093/eurheartj/ehae790. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Artificial intelligence (AI) algorithms in 12-lead electrocardiogram (ECG) provides promising age prediction methods. This study investigated whether the discrepancy between ECG-derived AI-predicted age (AI-ECG age) and chronological age, termed electrocardiographic aging (ECG aging), is associated with atrial fibrillation (AF) risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: An AI-ECG age prediction model was developed using a large-scale dataset (1 533 042 ECGs from 689 639 participants) and validated with six independent and multi-national datasets (737 133 ECGs from 330 794 participants). The AI-ECG age gap was calculated across two South Korean cohorts [mean (standard deviation) follow-up: 4.1 (4.3) years for 111 483 participants and 6.1 (3.8) years for 37 517 participants], one UK cohort [3.0 (1.6) years; 40 973 participants], and one US cohort [12.9 (8.6) years; 90 639 participants]. Participants were classified into two groups: normal group (age gap &lt; 7 years) and ECG-aged group (age gap ≥ 7 years). The predictive capability of ECG aging for new- and early-onset AF risk was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean AI-ECG ages were 51.9 (16.2), 47.4 (12.5), 68.4 (7.8), and 56.7 (14.6) years with age gaps of .0 (6.8), -.1 (6.0), 4.7 (8.7), and -1.4 (8.9) years in the two South Korean, UK, and US cohorts, respectively. In the ECG-aged group, increased risks of new-onset AF were observed with hazard ratios (95% confidence intervals) of 2.50 (2.24-2.78), 1.89 (1.46-2.43), 1.90 (1.55-2.33), and 1.76 (1.67-1.86) in the two South Korean, UK, and US cohorts, respectively. For early-onset AF, odds ratios were 2.89 (2.47-3.37), 1.94 (1.39-2.70), 1.58 (1.06-2.35), and 1.79 (1.62-1.97) in these cohorts compared with the normal group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The AI-derived ECG aging was associated with the risk of new- and early-onset AF, suggesting its potential utility to identify individuals for AF prevention across diverse populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626169/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39626169</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae790>10.1093/eurheartj/ehae790</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626169</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Seunghoon Cho</dc:creator>
<dc:creator>Sujeong Eom</dc:creator>
<dc:creator>Daehoon Kim</dc:creator>
<dc:creator>Tae-Hoon Kim</dc:creator>
<dc:creator>Jae-Sun Uhm</dc:creator>
<dc:creator>Hui-Nam Pak</dc:creator>
<dc:creator>Moon-Hyoung Lee</dc:creator>
<dc:creator>Pil-Sung Yang</dc:creator>
<dc:creator>Eunjung Lee</dc:creator>
<dc:creator>Zachi Itzhak Attia</dc:creator>
<dc:creator>Paul Andrew Friedman</dc:creator>
<dc:creator>Seng Chan You</dc:creator>
<dc:creator>Hee Tae Yu</dc:creator>
<dc:creator>Boyoung Joung</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-derived electrocardiographic aging and risk of atrial fibrillation: a multi-national study</dc:title>
<dc:identifier>pmid:39626169</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae790</dc:identifier>
</item>
<item>
<title>Artificial intelligence and digital tools for design and execution of cardiovascular clinical trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39626166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials. Advances in domain tasks such as automated diagnosis and classification, synthesis of high-volume data and latent data from adjacent modalities, patient discovery, telemedicine, remote monitoring, augmented reality, and in silico modelling have the potential to enhance the efficiency, accuracy, and cost-effectiveness of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 29:ehae794. doi: 10.1093/eurheartj/ehae794. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent advances have given rise to a spectrum of digital health technologies that have the potential to revolutionize the design and conduct of cardiovascular clinical trials. Advances in domain tasks such as automated diagnosis and classification, synthesis of high-volume data and latent data from adjacent modalities, patient discovery, telemedicine, remote monitoring, augmented reality, and in silico modelling have the potential to enhance the efficiency, accuracy, and cost-effectiveness of cardiovascular clinical trials. However, early experience with these tools has also exposed important issues, including regulatory barriers, clinical validation and acceptance, technological literacy, integration with care models, and health equity concerns. This narrative review summarizes the landscape of digital tools at each stage of clinical trial planning and execution and outlines roadblocks and opportunities for successful implementation of digital tools in cardiovascular clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39626166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39626166</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae794>10.1093/eurheartj/ehae794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39626166</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jiun-Ruey Hu</dc:creator>
<dc:creator>John R Power</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence and digital tools for design and execution of cardiovascular clinical trials</dc:title>
<dc:identifier>pmid:39626166</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae794</dc:identifier>
</item>
<item>
<title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3. doi: 10.1161/CIR.0000000000001293. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Smokeless oral nicotine products are addictive, and their use has potential adverse effects on some but not all biomarkers of cardiovascular risk. The use of some types of these products, for instance, is associated with an increased mortality risk in those with ischemic heart or cerebrovascular disease. Similarly, smokeless tobacco has the potential to increase the risk of oral cancer, but the risks depend on the chemical composition of the product. The market of smokeless oral nicotine products has transformed since the last American Heart Association smokeless tobacco policy statement. Several varieties of tobacco-free oral nicotine products-including oral nicotine pouches; nontherapeutic nicotine gums, lozenges, and tablets; and nicotine gummies-have rapidly proliferated. The sales of oral nicotine pouches, in particular, have increased substantially; however, no data are available on their cardiovascular or health risks. In addition, synthetic (compared with tobacco-derived) nicotine has been used in some brands of oral nicotine products, but its cardiovascular and health effects have been inadequately studied. Robust public policy levers are identified to support ending addiction to all commercial tobacco products. Critical components and policy initiatives include clinicians emphasizing the prevention of tobacco product initiation and supporting cessation with established pharmacological and behavioral tobacco dependence treatment therapies as primary goals for achieving an end to commercial tobacco and nicotine addiction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39624904/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39624904</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001293>10.1161/CIR.0000000000001293</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39624904</guid>
<pubDate>Tue, 03 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Cheryl R Dennison Himmelfarb</dc:creator>
<dc:creator>Neal L Benowitz</dc:creator>
<dc:creator>Melissa D Blank</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Paul J Chase</dc:creator>
<dc:creator>Esa M Davis</dc:creator>
<dc:creator>Jessica L Fetterman</dc:creator>
<dc:creator>Brittney Keller-Hamilton</dc:creator>
<dc:creator>Oluwabunmi Ogungbe</dc:creator>
<dc:creator>Robert L Page</dc:creator>
<dc:creator>Mary Rezk-Hanna</dc:creator>
<dc:creator>Rose Marie Robertson</dc:creator>
<dc:creator>Laurie P Whitsel</dc:creator>
<dc:creator>American Heart Association Advocacy Coordinating Committee</dc:creator>
<dc:date>2024-12-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Smokeless Oral Nicotine Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39624904</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001293</dc:identifier>
</item>
<item>
<title>Long-QT Trafficking Map</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241205171050&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 3;150(23):1882-1884. doi: 10.1161/CIRCULATIONAHA.124.072169. Epub 2024 Dec 2.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39621763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">39621763</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11614379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241205171050&v=2.18.0.post9+e462414">PMC11614379</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072169>10.1161/CIRCULATIONAHA.124.072169</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39621763</guid>
<pubDate>Mon, 02 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Barry London</dc:creator>
<dc:date>2024-12-02</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-QT Trafficking Map</dc:title>
<dc:identifier>pmid:39621763</dc:identifier>
<dc:identifier>pmc:PMC11614379</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072169</dc:identifier>
</item>





























</channel>
</rss>